Integrated use of AI tumor volumetrics and advanced MRI to assess early response to Temferon™ in a Phase-2 GBM trial: a novel paradigm
IAG, Image Analysis Group, a strategic partner to life-sciences companies developing novel treatments, today announced that an important abstract on the use of Artificial Intellegence (AI) and advanced imaging in oncology was accepted to this year’s American Society Clinical Oncology Virtual Conference, ASCO21.
The below abstracts are based upon the data genenrated by IAG, Image Analysis Group and biotech partner Genenta Science‘s in the latest clinical research studies. These show how advanced imaging and integrated use of AI can aid cancer drug development by assessing response earlier and more accurately.
The accepted abstracts are:
Title: “Integrated use of AI tumor volumetrics and advanced MRI to assess early response to Temferon™ in a Phase-2 GBM trial: a novel paradigm.”
Authors: Sotirios Bisdas, Diana Dupont-Roettger, Valeria Cuccarini, Bernhard Gentner, Marica Eoli , Luigi Naldini, Fabio Ciceri, Gaetano Finocchiaro, Carlo Russo, Maria Grazia Bruzzone.
Title: “A phase I-IIa study of genetically modified Tie-2 expressing monocytes in patients with glioblastoma multiforme (TEM-GBM Study).”
Authors: Gaetano Finocchiaro, Bernhard Gentner, Francesca Farina, Alessia Capotondo, Marica Eoli, Elena Anghileri, Matteo Giovanni Carabba, Valeria Cuccarini, Francesco Di Meco, Federico Legnani, Bianca Pollo, Maria Grazia Bruzzone, Marco Saini, Paolo Ferroli, Roberto Pallini, Alessandro Olivi, Stefania Mazzoleni, Carlo Russo, Luigi Naldini, Fabio Ciceri.
Abstracts will be released by ASCO on May 19, 2021, at 5:00 PM EDT on www.abstracts.asco.org
To learn more about IAG’s work in oncology, join our scientific leadership team in a series of LIVE webinars:
Join IAG and WPD Pharmaceuticals’ Experts to Discuss the Potential of Advanced Imaging to Show Early Treatment Effects of Berubicin in Brain Cancer
The Role of Central Imaging in Successful Oncology Clinical Trials
Send your questions to email@example.com
Prof. Sotirios Bisdas is IAG’s Sn Director of Neuro-Oncology Research. He is a consultant neuroradiologist and MRI Lead in the Department of Neuroradiology at the National Hospital for Neurology in London, Senior Lecturer in Neuroradiology at the Institute of Neurology University College London, and Professor of Radiology at Eberhard Karls University in Tübingen, Germany. He has authored over 130 peer-reviewed publications and serves as member of the editorial board of several leading journals in Radiology and Neuroradiology. He is also reviewer for leading journals in Neuroimaging, member of the Executive Committee of the European Society of Head and Neck Radiology, and member of the Head and Neck committee of the European Society of Neuroradiology.
Dr. Diana Dupont-Roettger is Chief Scientific Alliance Officer. She is a Medical Computer Scientist by background with strong experience in novel imaging technologies and imaging markers and their role in clinical trials. She advises biopharmaceutical companies on the strategic use of advanced imaging to evaluate mechanism of action, enable precision medicine and accelerate drug development in immuno-oncology and neuro-oncology indications. Diana is actively working with biotech, pharma and investment funds helping to bridge the gap between academic research, business objectives and finances.
About Image Analysis Group (IAG)
IAG, Image Analysis Group is a unique partner to life sciences companies. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner. IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.
Learn more: www.ia-grp.com
Reach out: firstname.lastname@example.org
Follow the Company: Linkedin
Join us at BIO International Convention in Boston 5th-8th June 2023
Drug development ideas in osteoarthritis, psoriatic arthritis and scleroderma.
The Invitation-only network for founders &CEOs of the most successful scaleups.